Teva’s R&D chief Eric Hughes, M.D., Ph.D., has resigned one week after the company showcased its push to grow its innovative medicines business.
Hughes joined Teva in 2022 as executive vice president, global R&D, and chief medical officer. This week, the executive told Teva he intended to resign and accept an offer outside the company, details of which have yet to emerge. Hughes has stepped down but will assist Teva over the next few months to smooth the transition.
Teva named David Gardiner, M.D., its head of innovative medicines and clinical development, as transition lead for R&D. Gardiner, who will report to Teva CEO Richard Francis, will serve as transition lead until Teva names a permanent successor. Teva has begun looking for Hughes’ replacement.
The leadership change comes at a key moment for Teva’s R&D group. Since Hughes and Francis joined in 2022 and 2023, respectively, Teva has stepped up efforts to grow its innovative medicines business. Last week, the company showcased its progress, outlining its ambition to generate up to $7 billion from innovative medicines by 2030 and forecasting that its pipeline could deliver $10 billion in peak sales.
Teva impressed TD Cowen analysts, who said in a Nov. 11 note to investors that they came away from the R&D day “increasingly confident.” The company has built an R&D pipeline that could deliver one launch per year until 2030. That goal reflects efforts to improve an R&D organization that, by Teva’s admission, was advancing programs too slowly as recently as 2023.
Continued execution across trials will be key, TD Cowen analysts said. Missteps could hand the advantage to rivals in competitive areas. Teva has identified duvakitug as the candidate with the highest peak sales potential, predicting that the anti-TL1A antibody could generate up to $5 billion. Merck & Co. has posted phase 3 data on a rival asset and Roche expects (PDF) to report pivotal results next year.
Following Hughes’ resignation, Teva confirmed that its R&D strategy and priorities are unchanged. In a statement, Francis hailed Hughes’ role in building Teva’s R&D pipeline, capabilities and organization, adding that he leaves the company “well positioned for its next chapter.”
Hughes joined Teva from Vertex, where he headed clinical development and translational medicine. Earlier in his career, Hughes worked at Novartis, Bristol Myers Squibb and Merck Research Laboratories.